G. Caramori (Ferrara, Italy), N. Roche (Paris, France)
Activation of TRPV4 causes bronchoconstriction: A possible role in respiratory disease?
S. J. Bonvini, J. J. Adcock, M. S. Grace, K. E. Baker, M. A. Birrell, M. G. Belvisi (London, United Kingdom)
|   |
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
F. Daubeuf, M. Hachet-Haas, P. Gizzi, V. Gasparik, D. Bonnet, V. Utard, M. Hibert, N. Frossard, J. L. Galzi (Illkirch, France)
| |
The effect of N acetyl-de-O-sulphated heparin on leukocyte diapedesis in vivo
Y. Riffo-Vasquez, A. Somani, C. Page (London, United Kingdom)
| |
Inhibition of lung inflammation by a protein epitope mimetic (PEM) neutrophil elastase inhibitor, POL6014, in a sub-chronic tobacco smoke (TS) model in mice
O. Sellier-Kessler, M. Schmitt, A. Wach, E. Chevalier (Allschwil, Switzerland)
|  |
Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients
S. Lea, C. Harbron, J. Armstrong, N. Khan, K. Wreggett, D. Singh (Manchester, Macclesfield, United Kingdom; Molndal, Sweden)
| |
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease
I. Kilty, N. Clarke, D. Fairmain, D. Lamb, J. Mathias, D. Millan, K. Wright, C. Perros-Huguet, M. Yeadon (Cambridge, United States Of America; Sandwich, United Kingdom)
| |
ALX-0962, an anti-IgE Nanobody® with a dual mode of action
M. Rinaldi, T. Denayer, S. Thiolloy, L. C. Perez Tosar, M. A. Buyse, P. De Decker, E. De Witte, P. Meerts, J. Baumeister, J. B. Holz (Zwijnaarde, Ghent, Belgium)
| |
Effect of ambroxol and beclomethasone on LPS/TNF-alpha-induced neutrophil-related chemokines and nitrative stress in human bronchial epithelial cells
F. L. M. Ricciardolo, V. Sorbello, S. Benedetto, D. Paleari (Torino, Parma, Italy)
| |